This web site is intended to serve as an information resource for anaplastic large cell lymphoma (ALCL) patients and their families. On this site you can learn more about the type of cancer defined as ALCL, its treatment options and emerging therapies to fight the disease.

Brentuximab vedotin (SGN-35) is an investigational agent that is currently being evaluated in multiple clinical trials, including a phase II clinical trial for patients with relapsed or refractory systemic ALCL, and a phase II trial for patients who have previously participated in a brentuximab vedotin study. For more information about these trials, click on the links below to the clinicaltrials.gov listing. More information about brentuximab vedotin is also available in the Drugs in Development section of this site.

A phase 2 open label trial of SGN-35 for patients who have previously participated in an SGN-35 study

A phase II open label trial of SGN-35 for systemic anaplastic large cell lymphoma (enrollment complete)

Comments and feedback
If you have questions or comments, please send an email to clinicaltrials@seagen.com. ALCL.com will not reply to requests related to management of individual patients and should not be used as an alternative to consultation with the patient's health care professionals.

The contents of ALCL.com, such as text, graphics, images and other information on this site ("Content") are for informational purposes only.  The Content is not intended to be a substitute for professional medical advice, diagnosis or treatment.  Always seek the advice of your physician or other qualified health provider with any questions you may have regarding your specific medical condition.  Never disregard professional medical advice or delay in seeking it because of something you have read on the ALCL.com site.